BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, November 29, 2024
See today's BioWorld Asia
Home
» SCG collaborates with Singapore’s A*STAR on multispecific antibodies
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
SCG collaborates with Singapore’s A*STAR on multispecific antibodies
March 22, 2022
By
David Ho
No Comments
SCG Cell Therapy Pte. Ltd. has signed a collaboration agreement with Singapore’s Agency for Science, Technology and Research (A*STAR)’s Bioprocessing Technology Institute (BTI) to advance the development of multispecific antibodies.
BioWorld Asia
Deals and M&A
